In line with these studies, we observe that a higher neutrophilic miRNA-23a level is associated with moderate-to-severe stroke on admission and symptom improvement at 24 h after rtPA treatment, and the noncoding RNA score composed of miRNA-23a, miRNA-99a, and lncRNA H19 is associated with the infarct volume and symptom progression at 7 days after rtPA treatment. This evidence concerns the gene H19 and stroke disorder.